Therapeutic strategies in psoriasis patients with psoriatic arthritis: Focus on new agents

BioDrugs

Volumn 27, Issue 4, 2013, Pages 359-373

  Gan, Emily Yiping ^a   Chong, Wei Sheng ^a   Tey, Hong Liang ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APREMILAST; BIOLOGICAL PRODUCT; BRODALUMAB; CALCIPOTRIOL; CERTOLIZUMAB PEGOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DITHRANOL; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PIMECROLIMUS; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SECUKINUMAB; TACROLIMUS; TAZAROTENE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; USTEKINUMAB;

AMINOTRANSFERASE BLOOD LEVEL; ARTHROPATHY; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INFECTION RISK; INFESTATION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIPOPROTEIN BLOOD LEVEL; LIVER FIBROSIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG ALVEOLITIS; MALAISE; NAUSEA; NEUTROPHIL COUNT; NON MELANOMA SKIN CANCER; NONHUMAN; PATHOGENESIS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CARCINOMA; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 84880790149     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0025-6     Document Type: Review

References (127)

1. Feletar M, Foley P, Brown MA. Developments in psoriasis and psoriatic arthritis. Drug Discov Today Dis Mech. 2008;5:e47-54.
2. Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):31-5.
3. Rapp SR, Feldman SR, Exum L, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
4. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1373-83.
5. Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22:160-8.
6. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129:1339-50.
7. Raychaudhuri SR. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-93.
8. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52-72.
9. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-85.
10. Sanchez AP. Immunopathogenesis of psoriasis. An Bras Dermatol. 2010;85:747-9.
11. Costello P, Bresnihan B, O'Farrelly C, et al. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999;26:1117-24.
12. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001;60:316-21.
13. Ruderman EM. Evaluation and management of psoriatic arthritis: the role of biologic therapy. J Am Acad Dermatol. 2003;49:S125-32.
14. Fisher VS. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis. J Manag Care Pharm. 2005;11:33-55.
15. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. Phenotypic and functional features of TH-17 cells in psoriasis and psoriatic arthritis. Arthritis Rheum. 2008;58:S352.
16. Hebert HL, Ali FR, Bowes J, et al. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol. 2012;166:474-82.
17. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64:ii37-9.
18. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum. 1995;38:845-50.
19. Eder L, Chandran V, Pellett F, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2011;70:1594-8.
20. Bowes J, Eyre S, Flynn E, et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis. 2011;70:1016-9.
21. Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37:1508-12.
22. Tejasvi T, Stuart P, Nair R, et al. Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies [abstract no. FC05]. Br J Dermatol. 2008;159:1391.
23. Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor-α-gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93-6.
24. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-94.
25. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis. Drugs. 2005;65:1223-38.
26. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73.
27. Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012;38:373-86.
28. Scarpa R, Atteno M, Costa L, et al. Early psoriatic arthritis. J Rheumatol Suppl. 2009;83:26-7.
29. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50.
30. Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol. 2003;49:S66-77.
31. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652-9.
32. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-65.
33. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol. 2006;54:1013-8.
34. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823-6.
35. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368-77.
36. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64.
37. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
38. Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatol Treat. 2011;22:276-84.
39. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:5-70.
40. Stern RS. Lymphoma risk in psoriasis. Arch Dermatol. 2006;142:1132-5.
41. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001;16:1395-401.
42. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-8.
43. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-85.
44. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991;90:711-6.
45. Kalb Re, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2009;60:824-37.
46. Erickson AR, Reddy V, Vogelgesang SA, et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 1995;38:1115-9.
47. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol. 2005;6:357-63.
48. MacDonald A, Burden AD. Noninvasive monitoring for methotrexate hepatotoxicity. Br J Dermatol. 2005;152:405-8.
49. Chalmers RJG, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol. 2005;152:444-50.
50. Bray AP, Barnova I, Przemioslo R, et al. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol. 2012;166:1125-7.
51. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012;18:163-73.
52. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-74.
53. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short course cyclosporine (Neoral): a multicenter study. Br J Dermatol. 1997;136:527-30.
54. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporine (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicenter, randomized study; the PISCES study group. Br J Dermatol. 1999;141:283-91.
55. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001;2:41-7.
56. Mrowietz U, Farber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study; German multicenter study. J Am Acad Dermatol. 1995;33:470-5.
57. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36:423-32.
58. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, multi-blind trial. N Engl J Med. 1991;324:277-84.
59. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211-6.
60. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042-5.
61. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841-9.
62. Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001;7:366-70.
63. Reich K, Hummel KM, Beckman I, et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146:335-6.
64. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum. 2004;50:1939-50.
65. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238-49.
66. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs. 1999;58:1137-64.
67. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393-7.
68. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
69. Menter A, Tyring S, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-15.
70. Mease P, Gladman D, Ritchlin C, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum. 2005;52:3279-89.
71. Gladman D, Mease P, Ritchlin C, et al. Adalimumab for long-term treatment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trials. Arthritis Rheum. 2007;56:476-88.
72. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64.
73. Philipp S, Wilsmann-Theis D, Weyergraf A, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases. J Dtsch Dermatol Ges. 2012;10:821-37.
74. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192-9.
75. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603.
76. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
77. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
78. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
79. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649-57.
80. Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159:460-3.
81. Zacharie C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495-501.
82. Heiberg MS, Kaufmann C, Rodevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis. 2007;66:1038-42.
83. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-40.
84. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67:364-9.
85. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41:329-37.
86. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001;357:1842-7.
87. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.
88. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-74.
89. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-36.
90. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7.
91. Vermeire S, Norman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-31.
92. Lecluse LL, Piskin G, Mekkes JR, et al. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159:527-36.
93. Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naïve patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8.
94. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-15.
95. Xu Z, Vu P, Lee H, et al. Population pharmacokinetics of golimumab an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49:1056-70.
96. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-86.
97. Kavanaugh A, van der Heijde D, McInnes I, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504-17.
98. National Institute for Health and Clinical Excellence. Golimumab for the treatment of psoriatic arthritis. London, UK: National Institute for Health and Clinical Excellence, April 2011. NICE technology appraisal guidance no: 220.
99. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167:180-90.
100. Mease PJ, Fleischmann R, Deodhar A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID-PSA) [abstract no. LB0001]. The European League against Rheumatism; 2012 June 6-9, Berlin.
101. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22:56-60.
102. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results form a randomized, double blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-74.
103. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol. 2010;162:137-46.
104. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12.23 monoclonal antibody, in patients with psoriasis: 52-week results form a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84.
105. Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-28.
106. Gaffen SL, Kramer JM, Yu JJ, et al. The IL-17 cytokine family. Vitam Horm. 2006;74:255-82.
107. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-24.
108. Korn T, Betelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
109. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation [published erratum appears in Immunity 2011;35:649]. Immunity. 2011;35:596-610.
110. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182:5836-45.
111. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-9.
112. McInnes I, Sieper J, Braun J, et al. Anti-interleukin 17A monoclonal antibody secukinumab reduces signs and symptoms of psoriatic arthritis in a 24-week multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2011;63(Suppl 10):779.
113. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90.
114. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503-9.
115. Claveau D, Chen SL, O'Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4- bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) -phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752-60.
116. Eigler A, Siegmund B, Emmerich U, et al. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol. 1998;63:101-7.
117. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273-87.
118. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b, randomized, placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668-77.
119. Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol. 2012;67:139-47.
120. Schafer P, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159:842-55.
121. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24:1529-38.
122. Papp K, Zeldis J, Rohane P, et al. A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis [abstract no. P2614]. J Am Acad Dermatol. 2008;58:AB3(2 Suppl 2).
123. Papp K, Hu A, Day R. Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: results from a phase 2b, randomized, controlled study (PSOR-005) [abstract no. 273]. J Invest Dermatol. 2011;131.
124. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156-67.
125. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;11:7-41.
126. Fox DA. Kinase inhibition - a new approach to the treatment of rheumatoid arthritis. N Engl J Med. 2012;367:565-7.
127. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacological effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299-302.